ClinicalTrials.gg
Status unknownNCT04494269Updated Nov 9, 2020

A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls

A Phase 1 interventional study of Tegoprazan 50mg in Hepatic Impairment and Healthy, sponsored by HK inno.N Corporation. Status unknown at 3 sites in Korea, Republic of. Open to participants aged 19 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-09.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
19 Years to 70 Years
Sex
All
01

Study summary

The main purpose of this study is to compare the pharmacokinetic and safety of tegoprazan following single oral dose in subjects with hepatic impairment versus healthy control.

Read the detailed description

[Pharmacokinetic Assessment]

  • Measurements

    • Tegoprazan and desmethyl tegoprazan (M1) in blood and urine
  • Endpoints

    • Primary endpoints: AUClast and Cmax of tegoprazan and M1
    • Secondary endpoints: CL/F, t1/2, AUCinf, and fu of tegoprazan; CLrenal and Ae of tegoprazan and M1

[Safety Assessment]

  • Adverse events (AEs)
  • Clinical laboratory tests
  • Vital sign
  • Physical examination
  • Electrocardiogram (ECG)
02

Conditions studied

  • Hepatic Impairment
  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

[Healthy Control Group]

Inclusion Criteria:

  • Subjects aged 19 to 70(inclusive) years at the time of signing the form.
  • Subjects with a body weight of ≥ 50 kg and ≤ 90 kg at screening.
  • Subjects with , ALT, and ALP levels of ≤ 1.5 × reference range (ULN) with total \< 2 mg/dL and PT () \< 1.7 at screening.
  • Subjects who have no chronic disease or any congenital disease within the last 5 years and no pathological symptoms or findings as a result of an internal examination
  • Subjects who provide voluntary written informed consent to study participation after being informed of detailed explanation and fully understanding study objectives, procedures and characteristics of the product(IP).

Exclusion Criteria:

  • Subjects who show symptoms of acute disease at the time of screening.
  • Subjects with any disease related to ongoing cardiovascular problem, respiratory system, kidney, endocrine system, hematologic, central nervous system, mental health disorder, or malignant tumor.
  • Subjects with history or current evidence of gastrointestinal or hepatobiliary disease which may affect PK evaluation of the IP.
  • Subjects with history or current evidence of clinically significant to drugs containing any ingredient of proton pump inhibitors or potassium-competitive acid blockers and other drugs (such as aspirin and antibiotics).
  • Subjects with systolic blood pressure (BP) of \< 90 mmHg or > 160 mmHg, or diastolic BP of \< 50 mmHg or > 100 mmHg at screening.
  • Subjects who have received medication or food which may significantly affect absorption, distribution, metabolism, or elimination of study drug within 7 days prior to scheduled study treatment.
  • Subjects who have participated in any other clinical study or bioequivalence study and received investigational agent within 180 days prior to scheduled study treatment.
  • Subjects who have donated whole blood within 60 days prior to the scheduled study treatment, or has donated blood components or received transfusion within 30 days prior to scheduled study treatment.
  • Subjects who are unable to use a medically acceptable method throughout the study.
  • Subjects who are determined ineligible for study participation by the investigator for other reasons.

[Subjects with Hepatic Impairment]

Inclusion Criteria:

  • Subjects with chronic liver disease who meet any of the followings:

    • Chronic ;
    • Chronic ;
    • Alcoholic liver disease;
    • Non-alcoholic fatty liver disease; or
    • Liver fibrosis and cirrhosis.
  • Subjects aged 19 to 70 years (inclusive) at the time of signing the informed consent form.
  • Subjects with body weight of ≥ 50 kg and ≤ 90 kg with a of ≥ 18.0 kg/m2 and ≤ 30 kg/m2 at screening.
  • Subjects who meet any of following criteria:

    • AST, ALT, or ALP level > 1.5 × ULN at screening;
    • Total bilirubin ≥ 2 mg/dL at screening; or
    • PT (INR) ≥ 1.7 at screening.
  • Subjects who provide voluntary written informed consent to study participation after being informed of detailed explanation and fully understanding study objectives, procedures and characteristics of the IP.

Exclusion Criteria:

  • Subjects who show symptoms of acute disease at the time of screening.
  • Subjects with any clinically significant disease related to ongoing cardiovascular problem, respiratory system, kidney, endocrine system, hematologic, central nervous system, mental health disorder, or malignant tumor.
  • Subjects with a history or current evidence of gastrointestinal disease which may affect PK evaluation for the IP.
  • Subjects who have clinical changes to an estimated level that may affect PK evaluation of the study drug within 30 days prior to the scheduled dosing date.
  • Changes in existing medications including dosage regimen within 30 days prior to the scheduled dosing date.
  • Subjects with prior history or current evidence of clinically significant hypersensitivity to drugs containing any ingredient of proton pump inhibitors or potassium-competitive acid blockers and other drugs (such as aspirin and antibiotics).
  • Systolic BP of \< 90 mmHg or > 160 mmHg, or diastolic BP of \< 50 mmHg or > 100 mmHg at screening.
  • Any concomitant medications or foods which may significantly affect absorption, distribution, metabolism, or elimination of the study drug within 7 days prior to the scheduled dosing date.
  • Subjects who have participated in any other clinical study or bioequivalence study and received investigational agent within 180 days prior to scheduled study treatment.
  • Subjects who have donated whole blood within 60 days prior to the scheduled dosing date, or have donated blood components or received transfusion within 30 days prior to the scheduled dosing date.
  • Subjects who are unable to use medically acceptable contraceptive methods throughout the study.
  • Subjects who are determined to be ineligible for study participation by the investigator for other reasons.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Active comparator
    Subjects with normal hepatic function

    Single dose of Tegoprazan 50mg

    Drug: Tegoprazan 50mg

  • Experimental
    Subjects with mild hepatic impairment

    Single dose of Tegoprazan 50mg

    Drug: Tegoprazan 50mg

  • Experimental
    Subjects with moderate hepatic impairment

    Single dose of Tegoprazan 50mg

    Drug: Tegoprazan 50mg

  • Experimental
    Subjects with severe hepatic impairment

    Single dose of Tegoprazan 50mg

    Drug: Tegoprazan 50mg

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Assessment

    AUClast of tegoprazan and M1

    Time frame: Up to 48 hours

  2. Pharmacokinetic Assessment

    Cmax of tegoprazan and M1

    Time frame: Up to 48 hours

Secondary outcomes

  1. Pharmacokinetic Assessment

    CL/F of tegoprazan

    Time frame: Up to 48 hours

  2. Pharmacokinetic Assessment

    t½ of tegoprazan

    Time frame: Up to 48 hours

  3. Pharmacokinetic Assessment

    AUCinf of tegoprazan

    Time frame: Up to 48 hours

  4. Pharmacokinetic Assessment

    fu of tegoprazan

    Time frame: Up to 48 hours

  5. Pharmacokinetic Assessment

    CLrenal of tegoprazan and M1

    Time frame: Up to 48 hours

  6. Pharmacokinetic Assessment

    Ae of tegoprazan and M1

    Time frame: Up to 48 hours

07

Study locations

3 of 3 sites recruiting
  • Gachon University Gil Medical Center
    Incheon, Korea, Republic of
    Recruiting
  • CHA Bundang Medical Center
    Seongnam-si, Korea, Republic of
    Recruiting
  • Samsung Medical Center
    Seoul, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jun 2023, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2020
First posted
Jul 31, 2020
StartActual
Sep 8, 2020
Primary completionEst.
Jun 2023
CompletionEst.
Dec 2023
Last update
Nov 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04494269
Responsible party
Sponsor
First posted
Jul 31, 2020
Start date
Sep 8, 2020
Primary completion
Jun 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Nov 9, 2020

Study contacts

Youngshin Keum, R.Ph, Pharm.D
Contact
ys.keum@inno-n.com
+82-2-6477-0204
Seokuee Kim, MD, PhD
Contact
seokuee.kim@inno-n.com
+82-2-6477-0207
Jung-Ryul Kim, MD, PhD
study chair · Samsung Medical Center
Yang-Won Min, MD, PhD
principal investigator · Samsung Medical Center
Dong-Seong Shin, MD, PhD
principal investigator · Gachon University Gil Medical Center
Eon-Hye Kim, MD, PhD
principal investigator · CHA Bundang Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion